Xeris Biopharma Boosts 2025 Revenue Guidance Amid Strong Financial Performance
Xeris Biopharma Holdings Inc. has reported strong financial performance and raised its revenue guidance for 2025 to $260-275 million, driven by the success of its flagship product Recorlev.
- Xeris Biopharma Holdings Inc
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read